Principia Biopharma (PRNB) Stock Price, News & Analysis

Company Overview

Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $100.05 to $100.05
• 50-Day Range: $99.95 to $100.27
• 52-Week Range: $25.35 to $101.89
• Volume: N/A
• Average Volume: 729,676 shs
• Market Capitalization: $3.32 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PRNB Stock Analysis - Frequently Asked Questions

How were Principia Biopharma's earnings last quarter?

Principia Biopharma Inc. (NASDAQ:PRNB) announced its earnings results on Thursday, August, 6th. The company reported $0.31 EPS for the quarter, beating analysts' consensus estimates of ($1.03) by $1.34. The company had revenue of $50 million for the quarter, compared to analyst estimates of $50 million.

When did Principia Biopharma IPO?

Principia Biopharma (PRNB) raised $75 million in an initial public offering on Friday, September 14th 2018. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

What other stocks do shareholders of Principia Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Principia Biopharma investors own include Pfizer (PFE), Advanced Micro Devices (AMD), AbbVie (ABBV), Bristol Myers Squibb (BMY), Cisco Systems (CSCO), QUALCOMM (QCOM) and VBI Vaccines (VBIV).

Company Calendar

• Last Earnings: 8/06/2020
• Today: 9/06/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:PRNB
• CIK: N/A
• Web: www.principiabio.com
• Phone: 650-416-7700
• Fax: N/A
• Employees: 65
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$53.79 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -23.08%
• Return on Assets: -21.11%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 17.01
• Quick Ratio: 17.01

Sales & Book Value

• Annual Sales: $35.16 million
• Price / Sales: 94.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.95 per share
• Price / Book: 9.14

Miscellaneous

• Outstanding Shares: 33,209,000
• Free Float: N/A
• Market Cap: $3.32 billion
• Optionable: Not Optionable
• Beta: 0.86